Rejuvenate bio banks to invest $10M in gene therapy for humans and dogs
Rejuvenate Bio offers a treatment that is a form of gene therapy. It increases the expression of sTGFbetaR2 to lower levels of TGF-beta1 cytokine and increase levels of FGF21 hormone. Both genes are linked to longevity.
Oliver explained that the combination of two genes can affect multiple age related diseases simultaneously.
In November 2019, Rejuvenate Bio released data showing that targeting two genes in mice reversed Type 2 diabetes and weight gain. The company gave mice extra copies of these genes alone or in combination with another gene, alpha-Klotho, to see if it could improve their health and lifespan. The company found that giving mice all three genes at once did not improve their health and life expectancy.
Source:
https://www.fiercebiotech.com/biotech/rejuvenate-bio-banks-10m-to-advance-gene-therapy-for-aging-humans-and-dogs
